Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10050387 | 0.91 | EDNRB (0.39) | ALOX5APFEN1EDNRBEDNRACYP2C9 | |
| SCHEMBL2706736 | 0.89 | FEN1 (0.38) | ALOX5APFEN1 | |
| SCHEMBL2705681 | 0.89 | KIF11 (0.36) | MYCWDR5 | |
| SCHEMBL2706844 | 0.89 | KDM4E (0.33) | — | |
| SCHEMBL2706881 | 0.87 | KIF11 (0.35) | MYCWDR5 | |
| SCHEMBL2706870 | 0.86 | CTSS (0.40) | — | |
| SCHEMBL2706779 | 0.85 | CTSS (0.34) | — | |
| SCHEMBL16002367 | 0.85 | ALOX5AP (0.40) | ALOX5APFEN1EDNRBEDNRACYP2C9 | |
| SCHEMBL2705380 | 0.85 | CTSS (0.38) | — | |
| SCHEMBL2706790 | 0.84 | KIF11 (0.36) | MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088901-B2 | Azaindenofluorenedione derivative, material for organic electroluminescence device and organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090315022-A1 | AZAINDENOFLUORENEDIONE DERIVATIVE, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090315022-A1 | AZAINDENOFLUORENEDIONE DERIVATIVE, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE | CYP19A1, HSD17B2, AZI2 | ALOX5AP 1795/4885FEN1 757/4885EDNRB 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.